We are live on
!
Find out more
VA
Verdad Advisers Portfolio holdings
AUM
$104M
This Fund
S&P 500
This Quarter
Est. Return
+21.07%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$104M
AUM Growth
+$15.6M
(+18%)
Cap. Flow
+$3.28M
Cap. Flow
% of AUM
3.14%
Top 10 Holdings %
Top 10 Hldgs %
18.12%
Holding
276
New
97
Increased
59
Reduced
42
Closed
66
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$2.13M |
| 2 |
Protara Therapeutics
TARA
|
+$1.49M |
| 3 |
X4 Pharmaceuticals
XFOR
|
+$1.44M |
| 4 |
Tyra Biosciences
TYRA
|
+$1.19M |
| 5 |
JBIO
Jade Biosciences
JBIO
|
+$1.18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Micron Technology
MU
|
+$2.57M |
| 2 |
Revolution Medicines
RVMD
|
+$2.56M |
| 3 |
State Street
STT
|
+$2.11M |
| 4 |
Autohome
ATHM
|
+$2.11M |
| 5 |
Cal-Maine
CALM
|
+$1.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 50.7% |
| 2 | Technology | 15.71% |
| 3 | Financials | 9.07% |
| 4 | Communication Services | 7.06% |
| 5 | Consumer Discretionary | 5.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Ultragenyx Pharmaceutical
RARE
$1.55B
| $208K | 0.2% |
+6,223
| New | +$155K |
|
152
FedEx
FDX
$76.4B
| $205K | 0.2% |
+654
| New | +$238K |
|
153
Adeia
ADEA
$2.91B
| $204K | 0.2% |
+6,183
| New | +$182K |
|
154
OneSpan
OSPN
$612M
| $203K | 0.19% |
+14,112
| New | +$178K |
|
155
Entrada Therapeutics
TRDA
$278M
| $202K | 0.19% |
+27,500
| New | +$264K |
|
156
IDEAYA Biosciences
IDYA
$3.84B
| $201K | 0.19% |
+5,400
| New | +$165K |
|
157
Nu Skin
NUS
$235M
| $195K | 0.19% |
36,999
+827
| +2% | +$5.29K |
|
158
Zentalis Pharmaceuticals
ZNTL
$377M
| $192K | 0.18% |
+39,608
| New | +$158K |
|
159
Riskified
RSKD
$857M
| $180K | 0.17% |
35,637
+17,455
| +96% | +$81.4K |
|
160
ALX Oncology
ALXO
$278M
| $170K | 0.16% |
+82,200
| New | +$147K |
|
|
AMRN
161
Amarin Corp
AMRN
$288M
| $166K | 0.16% |
+10,431
| New | +$154K |
|
162
eGain
EGAN
$158M
| $166K | 0.16% |
26,288
| – | – |
|
163
1stdibs.com
DIBS
$161M
| $160K | 0.15% |
32,661
-5,142
| -14% | -$24.8K |
|
164
Kodak
KODK
$907M
| $154K | 0.15% |
16,671
+1,876
| +13% | +$20.6K |
|
|
UPB
165
Upstream Bio Inc
UPB
$335M
| $151K | 0.14% |
+21,810
| New | +$183K |
|
166
Invivyd
IVVD
$237M
| $150K | 0.14% |
172,376
+41,100
| +31% | +$51.5K |
|
167
Passage Bio
PASG
$15.4M
| $150K | 0.14% |
30,728
+8,600
| +39% | +$53.8K |
|
168
Nkarta
NKTX
$201M
| $146K | 0.14% |
+51,503
| New | +$145K |
|
169
Annexon
ANNX
$923M
| $144K | 0.14% |
25,300
-27,977
| -53% | -$155K |
|
170
Lexeo Therapeutics
LXEO
$400M
| $142K | 0.14% |
+30,591
| New | +$165K |
|
171
The Beachbody Company
BODI
$42.2M
| $142K | 0.14% |
+13,921
| New | +$160K |
|
172
Verrica Pharmaceuticals
VRCA
$91.7M
| $141K | 0.14% |
23,069
+10,971
| +91% | +$68.4K |
|
173
Pyxis Oncology
PYXS
$325M
| $135K | 0.13% |
+44,899
| New | +$85.9K |
|
|
OKUR
174
OnKure Therapeutics
OKUR
$143M
| $131K | 0.13% |
+28,660
| New | +$123K |
|
175
Werewolf Therapeutics
HOWL
$46M
| $126K | 0.12% |
348,709
+318,949
| +1,072% | +$194K |
|
Similar funds
IAP
JRSI
SFG
TPW
ACM
TOTUOP
XFP
ICVCFVA
Verdad Advisers's Q2 2026 Portfolio in Review
As of Q2 2026, Verdad Advisers held 276 positions worth $104M, up 18% from $88.8M the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Verdad Advisers deployed $3.28M of net new capital in Q2 2026, opening 97 new positions and adding to 59 existing holdings. Its largest new stake was Apple: 7,445 shares worth $2.15M.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 42% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Micron Technology, an estimated $2.57M trimmed.
- Verdad Advisers's largest Q2 2026 buy was Apple: 7,445 shares worth $2.15M.
- Verdad Advisers added most to Comcast in Q2 2026, an estimated $1.11M increase.
- Verdad Advisers's biggest Q2 2026 reduction was Micron Technology, cutting an estimated $2.57M.
- Verdad Advisers fully exited State Street in Q2 2026, selling an estimated $2.11M.
- Verdad Advisers's ten largest holdings make up 18% of its $104M portfolio in Q2 2026.
- Verdad Advisers opened 97 new positions and closed 66 in Q2 2026.
- Verdad Advisers's portfolio value rose 18% quarter-over-quarter to $104M.
Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.